Insights into sympathetic nervous system and GPCR interplay in fetal programming of hypertension: a bridge for new pharmacological strategies

• Type: Another Publication in an International Scientific Journal
• Date: 2020

Authors

Vieira Rocha, MS (Author) Other; Sousa, JB (Author) Other; Rodriguez Rodriguez, P (Author) Other; Morato, M (Author) FFUP; Arribas, SM (Author) Other; Diniz, C (Author) FFUP

Journal

Title: Drug Discovery Today

Vol. 25

Pages: 739-747

ISSN: 1359-6446

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 1 Citation

Other information

Authenticus ID: P-00R-S10

DOI: 10.1016/j.drudis.2020.01.019

Abstract (EN): Cardiovascular diseases (CVDs) are the most common cause of death from noncommunicable diseases worldwide. In addition to the classical CVD risk factors related to lifestyle and/or genetic background, exposure to an adverse intrauterine environment compromises fetal development leading to low birth weight and increasing offspring susceptibility to develop CVDs later in life, particularly hypertension - a process known as fetal programming of hypertension (FPH). In FPH animal models, permanent alterations have been detected in gene expression, in the structure and function of heart and blood vessels, compromising cardiovascular physiology and favoring hypertension development. This review focuses on the role of the sympathetic nervous system and its interplay with G-protein-coupled receptors, emphasizing strategies that envisage the prevention and/or treatment of FPH through interventions in early life.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9